338 related articles for article (PubMed ID: 23665398)
1. Hyperuricemia influences tryptophan metabolism via inhibition of multidrug resistance protein 4 (MRP4) and breast cancer resistance protein (BCRP).
Dankers AC; Mutsaers HA; Dijkman HB; van den Heuvel LP; Hoenderop JG; Sweep FC; Russel FG; Masereeuw R
Biochim Biophys Acta; 2013 Oct; 1832(10):1715-22. PubMed ID: 23665398
[TBL] [Abstract][Full Text] [Related]
2. Uremic toxins inhibit transport by breast cancer resistance protein and multidrug resistance protein 4 at clinically relevant concentrations.
Mutsaers HA; van den Heuvel LP; Ringens LH; Dankers AC; Russel FG; Wetzels JF; Hoenderop JG; Masereeuw R
PLoS One; 2011 Apr; 6(4):e18438. PubMed ID: 21483698
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the role of breast cancer resistance protein (BCRP/ABCG2) and multidrug resistance-associated protein 4 (MRP4/ABCC4) in the urinary excretion of sulfate and glucuronide metabolites of edaravone (MCI-186; 3-methyl-1-phenyl-2-pyrazolin-5-one).
Mizuno N; Takahashi T; Kusuhara H; Schuetz JD; Niwa T; Sugiyama Y
Drug Metab Dispos; 2007 Nov; 35(11):2045-52. PubMed ID: 17682070
[TBL] [Abstract][Full Text] [Related]
4. Hyperuricemia enhances intracellular urate accumulation via down-regulation of cell-surface BCRP/ABCG2 expression in vascular endothelial cells.
Komori H; Yamada K; Tamai I
Biochim Biophys Acta Biomembr; 2018 May; 1860(5):973-980. PubMed ID: 29317200
[TBL] [Abstract][Full Text] [Related]
5. Sulfonation of raloxifene in HEK293 cells overexpressing SULT1A3: Involvement of breast cancer resistance protein (BCRP/ABCG2) and multidrug resistance-associated protein 4 (MRP4/ABCC4) in excretion of sulfate metabolites.
Zhou X; Wang S; Sun H; Wu B
Drug Metab Pharmacokinet; 2015 Dec; 30(6):425-33. PubMed ID: 26611713
[TBL] [Abstract][Full Text] [Related]
6. Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor.
Yamada A; Maeda K; Kamiyama E; Sugiyama D; Kondo T; Shiroyanagi Y; Nakazawa H; Okano T; Adachi M; Schuetz JD; Adachi Y; Hu Z; Kusuhara H; Sugiyama Y
Drug Metab Dispos; 2007 Dec; 35(12):2166-76. PubMed ID: 17823233
[TBL] [Abstract][Full Text] [Related]
7. Solitary Inhibition of the Breast Cancer Resistance Protein Efflux Transporter Results in a Clinically Significant Drug-Drug Interaction with Rosuvastatin by Causing up to a 2-Fold Increase in Statin Exposure.
Elsby R; Martin P; Surry D; Sharma P; Fenner K
Drug Metab Dispos; 2016 Mar; 44(3):398-408. PubMed ID: 26700956
[TBL] [Abstract][Full Text] [Related]
8. Ex vivo resistance in childhood acute lymphoblastic leukemia: Correlations between BCRP, MRP1, MRP4 and MRP5 ABC transporter expression and intracellular methotrexate polyglutamate accumulation.
Jaramillo AC; Cloos J; Lemos C; Stam RW; Kaspers GJL; Jansen G; Peters GJ
Leuk Res; 2019 Apr; 79():45-51. PubMed ID: 30849662
[TBL] [Abstract][Full Text] [Related]
9. Reactive oxygen species derived from xanthine oxidase interrupt dimerization of breast cancer resistance protein, resulting in suppression of uric acid excretion to the intestinal lumen.
Ogura J; Kuwayama K; Sasaki S; Kaneko C; Koizumi T; Yabe K; Tsujimoto T; Takeno R; Takaya A; Kobayashi M; Yamaguchi H; Iseki K
Biochem Pharmacol; 2015 Sep; 97(1):89-98. PubMed ID: 26119820
[TBL] [Abstract][Full Text] [Related]
10. High-throughput screening identifies Ceefourin 1 and Ceefourin 2 as highly selective inhibitors of multidrug resistance protein 4 (MRP4).
Cheung L; Flemming CL; Watt F; Masada N; Yu DM; Huynh T; Conseil G; Tivnan A; Polinsky A; Gudkov AV; Munoz MA; Vishvanath A; Cooper DM; Henderson MJ; Cole SP; Fletcher JI; Haber M; Norris MD
Biochem Pharmacol; 2014 Sep; 91(1):97-108. PubMed ID: 24973542
[TBL] [Abstract][Full Text] [Related]
11. Interaction of immunosuppressive drugs with human organic anion transporter (OAT) 1 and OAT3, and multidrug resistance-associated protein (MRP) 2 and MRP4.
El-Sheikh AA; Greupink R; Wortelboer HM; van den Heuvel JJ; Schreurs M; Koenderink JB; Masereeuw R; Russel FG
Transl Res; 2013 Dec; 162(6):398-409. PubMed ID: 24036158
[TBL] [Abstract][Full Text] [Related]
12. Uric acid transporters BCRP and MRP4 involved in chickens uric acid excretion.
Ding X; Li M; Peng C; Wang Z; Qian S; Ma Y; Fang T; Feng S; Li Y; Wang X; Li J; Wu J
BMC Vet Res; 2019 May; 15(1):180. PubMed ID: 31146764
[TBL] [Abstract][Full Text] [Related]
13. Inhibitory potential of tuberculosis drugs on ATP-binding cassette drug transporters.
Te Brake LH; Russel FG; van den Heuvel JJ; de Knegt GJ; de Steenwinkel JE; Burger DM; Aarnoutse RE; Koenderink JB
Tuberculosis (Edinb); 2016 Jan; 96():150-7. PubMed ID: 26682943
[TBL] [Abstract][Full Text] [Related]
14. Inhibitory effects of terpenoids on multidrug resistance-associated protein 2- and breast cancer resistance protein-mediated transport.
Yoshida N; Takada T; Yamamura Y; Adachi I; Suzuki H; Kawakami J
Drug Metab Dispos; 2008 Jul; 36(7):1206-11. PubMed ID: 18436619
[TBL] [Abstract][Full Text] [Related]
15. Interaction Studies of Resolvin E1 Analog (RX-10045) with Efflux Transporters.
Cholkar K; Trinh HM; Vadlapudi AD; Wang Z; Pal D; Mitra AK
J Ocul Pharmacol Ther; 2015 May; 31(4):248-55. PubMed ID: 25844889
[TBL] [Abstract][Full Text] [Related]
16. In vitro characterization of axitinib interactions with human efflux and hepatic uptake transporters: implications for disposition and drug interactions.
Reyner EL; Sevidal S; West MA; Clouser-Roche A; Freiwald S; Fenner K; Ullah M; Lee CA; Smith BJ
Drug Metab Dispos; 2013 Aug; 41(8):1575-83. PubMed ID: 23729661
[TBL] [Abstract][Full Text] [Related]
17. Effects of aripiprazole and its active metabolite dehydroaripiprazole on the activities of drug efflux transporters expressed both in the intestine and at the blood-brain barrier.
Nagasaka Y; Oda K; Iwatsubo T; Kawamura A; Usui T
Biopharm Drug Dispos; 2012 Sep; 33(6):304-15. PubMed ID: 22847220
[TBL] [Abstract][Full Text] [Related]
18. Zinc finger nuclease-mediated gene knockout results in loss of transport activity for P-glycoprotein, BCRP, and MRP2 in Caco-2 cells.
Sampson KE; Brinker A; Pratt J; Venkatraman N; Xiao Y; Blasberg J; Steiner T; Bourner M; Thompson DC
Drug Metab Dispos; 2015 Feb; 43(2):199-207. PubMed ID: 25388687
[TBL] [Abstract][Full Text] [Related]
19. Cetuximab Prevents Methotrexate-Induced Cytotoxicity in Vitro through Epidermal Growth Factor Dependent Regulation of Renal Drug Transporters.
Caetano-Pinto P; Jamalpoor A; Ham J; Goumenou A; Mommersteeg M; Pijnenburg D; Ruijtenbeek R; Sanchez-Romero N; van Zelst B; Heil SG; Jansen J; Wilmer MJ; van Herpen CML; Masereeuw R
Mol Pharm; 2017 Jun; 14(6):2147-2157. PubMed ID: 28493713
[TBL] [Abstract][Full Text] [Related]
20. Disposition of Mianserin and Cyclizine in UGT2B10-Overexpressing Human Embryonic Kidney 293 Cells: Identification of UGT2B10 as a Novel N-Glucosidation Enzyme and Breast Cancer Resistance Protein as an N-Glucoside Transporter.
Lu D; Dong D; Xie Q; Li Z; Wu B
Drug Metab Dispos; 2018 Jul; 46(7):970-979. PubMed ID: 29691239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
